HER2

105개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved105 programs
ADCLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Patritumab and Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 4Status Recruiting
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, SD-101 + Pembrolizumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 4Status Recruiting
CGTLimited DatastaleSanofiPhase 1

Universal Donor Expanded TGF-beta-imprinted NK Cells (Universal Donor Expanded TGF-beta-imprinted NK Cells)

Recurrent Multiple Myeloma; Refractory Multiple Myeloma · HER2

#HER2#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 4Status Active
AntibodyLimited DatastaleRegeneronPhase 2

VV1 + Cemiplimab (VV1 + Cemiplimab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 4Status Recruiting
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, AMG 386 and Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 2Status Recruiting
AntibodyLimited DatastaleRochePhase 3

HLX87 + Pertuzumab (HLX87 + Pertuzumab)

HER2 + Breast Cancer · HER2

#HER2#Antibody#Phase3#monoclonal-antibody#HER2+BreastCancer+1
Trials 2Status Recruiting
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, MK-2206 with or without Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 2Status Recruiting
AntibodyLimited DatastaleMargaret Gatti-MaysPhase 2

Naxitamab (Naxitamab)

Anatomic Stage IV Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AnatomicStageIVBreastCancerAJCCv+2
Trials 2Status Recruiting
AntibodyLimited DatastaleQuantumLeap Healthcare Collabor…Phase 2

trastuzumab (Herceptin, AMG 386 with or without Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Recruiting
AntibodyLimited DatastaleQuantumLeap Healthcare Collabor…Phase 2

ARX788 + Cemiplimab (ARX788 + Cemiplimab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 1

Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER, Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor, Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Active
CGTLimited DatastaleZhi YangPhase 2

Anti-HER2 CAR-T (Anti-HER2 CAR-T)

Breast Cancer; Ovarian Cancer · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleEssen BiotechPhase 2

CD146/HER2 CAR-T cells (CD146/HER2 CAR-T cells)

Sarcoma; Sarcoma, Kaposi · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleFudan UniversityPhase 2

Carrelizumab (Carrelizumab)

Breast Neoplasm; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasm+2
Trials 1Status Recruiting
CGTLimited DatastaleNational University Hospital, S…Phase 2

trastuzumab (Herceptin, Chimeric receptor T-cells + Trastuzumab)

HER2+ Advanced Breast Cancer; Other Solid Tumors · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
ADCLimited DatastaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Fruquintinib)

HER2; Colorectal Cancer · HER2

#HER2#ADC#Approved#antibody-drug-conjugate#ColorectalCancer+1
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Toripalimab)

Muscle Invasive Bladder Cancer; HER2 Expression · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#MuscleInvasiveBladderCancer+2
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Radiotherapy)

HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-expressingHigh-riskorVeryHi+1
Trials 1Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with fruquintinib and Tislelizumab)

HER2-positive Gastric Cancer; Immunotherapy · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveGastricCancer+2
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab vedotin + Sintilimab + Multimodality radiotherapy)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveAdvancedGastricCanc+1
Trials 1Status Recruiting

3 / 6 pages

← PreviousNext →